Recent weeks have seen soaring COVID-19 cases across China, pushing many people to various domestic health platforms in an attempt to purchase coveted antiviral medication and fever-reduction pills.
Due to the rapid increase of COVID-19 infection cases in China, the demand for Pfizer's pill Paxlovid has also greatly increased. As the drug is being hyped by drug scalpers, the price of Paxlovid on third-party channels has climbed to tens of thousands of yuan, which is nearly six times more expensive than the normal price of 2,000 yuan ($287).
As the Omicron coronavirus variant spreads across China, the risk of silent hypoxia to the elderly population has received significant attention. As an effective means to monitor blood oxygen level and prevent critical illness, oximeters are now selling rapidly.
With the recent lifting of pandemic control policies in China, the number of infections has risen sharply. Chinese internet giant Tencent launched a "COVID-19 Pills Mutual Help Public Welfare Platform."
On the evening of December 13, Fosun Pharma, the exclusive commercial partner of Chinese COVID-19 oral drug Azvudine, confirmed that the pills can soon be prescribed through online medical platforms.
With the recent relaxation of the Chinese government's zero COVID policy, drugs for flu symptoms and fever such as Ibuprofen and Lianhua Qingwen, antigen test kits and vitamin C tablets are out of stock in pharmacies and e-commerce platforms.
Ashermed, a digital clinical research organization (CRO) focusing on the post-launch services market for innovative medical equipment, announced the completion of round-B financing of over $14.86 million.
Intelligent robotics developer Agile Robots has recently completed a financing round totaling $30 million led by Foxconn Industrial Internet.
Fourier Intelligence, a Chinese smart rehab startup known for its robotic exoskeletons, recently received 400 million yuan ($63.27 million) in series D financing.
Medical device maker JancsiTech announced the completion of its most recent round of financing. This round was led by Sequoia China Seed Fund.
Beijing Changmugu Medical Technology, a provider of integrated solutions for orthopedic intelligent surgery, announced that it had recently completed a Series B round of financing in which it secured 540 million yuan ($84.3 million).
This round of finaning was led by Alibaba Health and followed by Ether Capital. China Renaissance acted as the exclusive financial adviser to the deal.
Its lead investor in this round is Boyu Capital, while co-leading investors are Temasek and Sequoia China. Existing investors such as 3H Health Investment, LYFE Capital and Guoce Capital also participated in this round.
Chinese medical technology firm magAssist has completed a C round of financing worth nearly 500 million yuan ($78 million), led by Sequoia China, followed by CDH Innovation and Growth Fund and Cenova Capital.
On October 8th, Guangdong Provincial Food and Drug Administration announced that Huawei's "single-guide ECG blood pressure wrist device" was officially approved for production.
To increase Guangzhou's capacity to administer nucleic acid tests, which are used to screen those suspected of being infected with COVID-19, four groups of inflatable COVID-19 testing labs are being put into use in the vast metropolis in the Chinese province of Guangdong.
In last week’s VC news across China, logistics upstart YQNLink bags a whopping $100 million in its latest round, Hong Kong-based investment firm Gaw Capital Partners closes a further $430 million in funds, robotics startup MegaRobo closes a hefty $65 million investment round while Suzhou’s IntoCare Medical rakes in more than $15 million in its Series D fundraising round.
China has given conditional approval for the general public use of a Covid-19 vaccine developed by Sinovac Biotech, making it the second home-made vaccine to get the green light for mass inoculation.
During the early stage of the COVID-19 pandemic, scholars from Tsinghua University developed an integrative kit for quick coronavirus test.
Tencent, a virtual game developer giant in China, just played a "win-win" game in reality with a National Football League (NFL) team of the United States.